Plasmacytoid dendritic cells lead the charge against tumors

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 481-484

  Jiménez Baranda, Sonia ^a   Silva, Inês Pires ^a,b,c   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c Programme for Advanced Medical Education   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 7;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CELL MIGRATION; CELL TRANSFORMATION; HUMAN; INNATE IMMUNITY; KILLER CELL; MELANOMA; NONHUMAN; NOTE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; HUMANS; NEOPLASMS, EXPERIMENTAL;

EID: 84856552035     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61345     Document Type: Note

References (25)

1. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27(7):571-577. (Pubitemid 35463873)
2. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733. (Pubitemid 38580549)
3. Smyth EC, et al. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol. 2011;29(33):e809-e811.
4. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. 2010;16(4):382-391.
5. Li VW, Li WW, Talcott KE, Zhai AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4(6):708-717.
6. Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol. 2003;149(suppl 66):9-14.
7. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637-650.
8. Peng G, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005;309(5739):1380-1384. (Pubitemid 41209366)
9. Wei S, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65(12):5020-5026. (Pubitemid 40827308)
10. Drobits B, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012;122(2):575-585.
11. Heib V, et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood. 2007;110(3):946-953. (Pubitemid 47267433)
12. Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222-225.
13. Gazzaniga S, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol. 2007;127(8):2031-2041. (Pubitemid 47075380)
14. Sisirak V, et al. CCR6/CCR10-mediated plasmacytoid dendritic cells recruitment to inflamed epithelia following instruction in lymphoid tissues. Blood. 2011;118(19):5130-5140.
15. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204(6):1441-1451. (Pubitemid 46919881)
16. Sozzani S, Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010;31(7):270-277.
17. Chaperot L, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol. 2006;176(1):248-255. (Pubitemid 43023269)
18. Urosevic M, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97(15):1143-1153. (Pubitemid 41511214)
19. Hardy AW, Graham DR, Shearer GM, Herbeuval JP. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7- induced IFN-alpha. Proc Natl Acad Sci U S A. 2007;104(44):17453-17458. (Pubitemid 350219859)
20. Fuertes MB, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208(10):2005-2016.
21. Adams S, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008;181(1):776-784.
22. Liu C, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3):1165-1175. (Pubitemid 351364623)
23. Clark RA, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205(10):2221-2234.
24. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139(3):273-276. (Pubitemid 36330572)
25. Brody JD, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324-4332.